BMJ  2005;330:503 (5 March), doi:10.1136/bmj.38356.655266.82 (published 11 February 2005)

Paper

Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine

¹ Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy, Eschenallee 3, 14050 Berlin, Germany, ² Institute for Medical Research Management and Biometrics GmbH, Scheurlstraße 21, 90478 Nürnberg, Germany, ³ Dr Willmar Schwabe Pharmaceuticals, PO Box 410925, 76209 Karlsruhe, Germany

Objective To investigate the efficacy of hypericum extract WS 5570 (St John's wort) compared with paroxetine in patients with moderate to severe major depression.

Design Randomised double blind, double dummy, reference controlled, multicentre non-inferiority trial.

Setting 21 psychiatric primary care practices in Germany.

Participants 251 adult outpatients with acute major depression with total score 22 on the 17 item Hamilton depression scale.

Interventions 900 mg/day hypericum extract WS 5570 three times a day or 20 mg paroxetine once a day for six weeks. In initial non-responders doses were increased to 1800 mg/day hypericum or 40 mg/day paroxetine after two weeks.

Main outcome measures Change in score on Hamilton depression scale from baseline to day 42 (primary outcome). Secondary measures were change in scores on Montgomery-Åsberg depression rating scale, clinical global impressions, and Beck depression inventory.

Results The Hamilton depression total score decreased by mean 14.4 (SD 8.8) points, corresponding to 56.6% (SD 34.3%) of the baseline value, in the hypericum group and by 11.4 (SD 8.6) points (44.8% (SD 33.5%) of baseline value) in the paroxetine group (intention to treat analysis; similar results were observed in the per protocol analysis). The intention to treat analysis (lower one sided 97.5% confidence limit 1.5 points for the difference hypericum minus paroxetine) and the per protocol analysis (lower confidence limit 0.7 points) showed non-inferiority of hypericum and statistical superiority over paroxetine. The lower limits in both cases exceeded the pre-specified non-inferiority margin of -2.5 points and the superiority margin of 0. The incidence of adverse events was 0.035 and 0.060 events per day of exposure for hypericum and paroxetine, respectively.

Conclusions In the treatment of moderate to severe major depression, hypericum extract WS 5570 is at least as effective as paroxetine and is better tolerated.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

Complementary therapies and the NHS

Trevor Thompson and Gene Feder
BMJ 2005 331: 856-857. [Extract] [Full Text] [PDF]

Regulating herbal medicines in the UK

Robin E Ferner and Keith Beard
BMJ 2005 331: 62-63. [Extract] [Full Text] [PDF]

St John's wort is effective for moderate to severe depression
BMJ 2005 330: 0. [Full Text] [PDF]

This article has been cited by other articles:

• Enna, S. J., Williams, M. (2009). Challenges in the Search for Drugs to Treat Central Nervous System Disorders. J. Pharmacol. Exp. Ther. 329: 404-411 [Abstract] [Full text]  
• Carpenter, C., Crigger, N., Kugler, R., Loya, A. (2008). Hypericum and Nurses: A Comprehensive Literature Review on the Efficacy of St. John's Wort in the Treatment of Depression. J Holist Nurs 26: 200-207 [Abstract]  
• Weber, W., Vander Stoep, A., McCarty, R. L., Weiss, N. S., Biederman, J., McClellan, J. (2008). Hypericum perforatum (St John's Wort) for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Randomized Controlled Trial. JAMA 299: 2633-2641 [Abstract] [Full text]  
• Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L, Lewis, G, Matthews, K, McAllister-Williams, R., Peveler, R., Scott, J, Tylee, A (2008). Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 22: 343-396 [Abstract]  
• Leuner, K., Kazanski, V., Muller, M., Essin, K., Henke, B., Gollasch, M., Harteneck, C., Muller, W. E. (2007). Hyperforin a key constituent of St. John's wort specifically activates TRPC6 channels. FASEB J. 21: 4101-4111 [Abstract] [Full text]  
• WERNEKE, U., TURNER, T., PRIEBE, S. (2006). Complementary medicines in psychiatry: Review of effectiveness and safety. Br. J. Psychiatry 188: 109-121 [Abstract] [Full text]  
• Ernst, P. E. (2005). St John's wort is at least as effective as paroxetine in reducing severity of depression and is better tolerated. Evid. Based Ment. Health 8: 107-107 [Full text]  
• Thompson, T., Feder, G. (2005). Complementary therapies and the NHS. BMJ 331: 856-857 [Full text]  
• Block, K. I. (2005). Integrative Physician's Perspective, With a Special Consideration of St John's Wort. Integr Cancer Ther 4: 261-265  
• Ferner, R. E, Beard, K. (2005). Regulating herbal medicines in the UK. BMJ 331: 62-63 [Full text]  
• (2005). St. John's Wort vs. Paroxetine for Moderate-to-Severe Depression. JWatch Psychiatry 2005: 8-8 [Full text]  
• (2005). Hit parade. BMJ 330: 1155-1155 [Full text]  
• (2005). St. John's Wort vs. Paroxetine for Moderate-to-Severe Depression. JWatch General 2005: 2-2 [Full text]  

Rapid Responses:

Read all Rapid Responses

Seroxat 'v' St. John's Wort: an unfair contest?

Tim Watkins
bmj.com, 11 Feb 2005 [Full text]

St John's Wort Consumer

Jane CR Robertson
bmj.com, 20 Feb 2005 [Full text]

Re: Seroxat 'v' St. John's Wort: an unfair contest?

Stevie M Gamble
bmj.com, 24 Feb 2005 [Full text]

Re: Re: Seroxat 'v' St. John's Wort: an unfair contest?

Tim Watkins
bmj.com, 25 Feb 2005 [Full text]

On the necessity of placebo controls in clinical trials of hypericum extract

Brandon A. Gaudiano
bmj.com, 25 Feb 2005 [Full text]

Re: Re: Re: Seroxat 'v' St. John's Wort: an unfair contest?

Stevie M Gamble
bmj.com, 26 Feb 2005 [Full text]

I may have missed something

Nicholas D. Moore
bmj.com, 4 Mar 2005 [Full text]

St John's wort is a herbal SSRI?

AK Al-Sheikhli
bmj.com, 4 Mar 2005 [Full text]

Re: St John's wort is a herbal SSRI?

Phil Lucas
bmj.com, 4 Mar 2005 [Full text]

"Remission" not defined; safety not addressed

Richard Braithwaite
bmj.com, 4 Mar 2005 [Full text]

The Run-In Period is methodologically flawed

Yogi Sehgal
bmj.com, 5 Mar 2005 [Full text]

Re: I may have missed something

Stevie M Gamble
bmj.com, 5 Mar 2005 [Full text]

What is 'moderate to severe depression'?

Billy Boland
bmj.com, 5 Mar 2005 [Full text]

European Pharmaceutical Industry v. St. John's Wort.

Paul G Champion
bmj.com, 5 Mar 2005 [Full text]

For a herbal medicine to be effective, it must act as a drug

Samantha Line
bmj.com, 5 Mar 2005 [Full text]

Re: "Remission" not defined; safety not addressed

David A Forbes
bmj.com, 5 Mar 2005 [Full text]

Re: The Run-In Period is methodologically flawed

David Forbes
bmj.com, 5 Mar 2005 [Full text]

Re: On the necessity of placebo controls in clinical trials of hypericum extract

David Forbes
bmj.com, 5 Mar 2005 [Full text]

Acute treatment of depression with Hypericum versus paroxetine reconsidered

Henricus G Ruhe, et al.
bmj.com, 7 Mar 2005 [Full text]

St. John’s Wort - Issues of Clinical Importance.

Dr. Murali Krishna, et al.
bmj.com, 9 Mar 2005 [Full text]

Statistical analysis of adverse events

Adam Jacobs
bmj.com, 10 Mar 2005 [Full text]

Fishy five a day or Wort a day?

Srinivasan Ravi
bmj.com, 10 Mar 2005 [Full text]

Standards of WS 5570 are unacceptable

Arun S Nanivadekar
bmj.com, 10 Mar 2005 [Full text]

The depressing state of psychiatric research

Howard Mann
bmj.com, 11 Mar 2005 [Full text]

Side-effects of Hypericum extract

Keay G Smith
bmj.com, 21 Mar 2005 [Full text]

Controller and controlled

Daniel Sher
bmj.com, 6 Apr 2005 [Full text]

Re: Standards of WS 5570 are unacceptable

K. M. Phillips
bmj.com, 7 May 2005 [Full text]

Online poll

Find out more on doc2doc >>